STERIS reports its fiscal Q4 2026 results on May 11 — a print where attention will focus squarely on capital equipment recovery and whether recent operational gains can hold against a deteriorating order backlog.
Options positioning has edged more cautious ahead of the release. The put/call ratio is running at 1.31, modestly above its 20-day average of 1.14. That's not an extreme reading — the z-score sits at just 0.42 — but the direction is clear. Over the past month, the PCR has drifted higher, suggesting investors are incrementally adding downside protection rather than pressing calls.
The short side tells a quieter story. Short interest is thin at 1.5% of the free float, and has actually fallen sharply from around 2.0% in early April. The borrow market is wide open — cost to borrow is just 0.29%, down about 21% on the week and nearly 29% lower than a month ago. There is no meaningful squeeze pressure here, and no signal of conviction from short sellers heading into the print.
The debate around STERIS turns on two structural questions. Bulls point to solid revenue momentum: the most recent quarter showed organic growth of 5.0% year-over-year, a 14% EPS increase to $2.74, and an 110 basis point improvement in EBIT margins. The dental segment divestiture has simplified the story and reduced interest expense. Bears, meanwhile, are watching capital equipment sales, which dropped roughly 16% year-over-year last quarter. Service revenues fell 21% over the same period, and the equipment backlog shrank by $66 million quarter-on-quarter. That combination — consumables growing, but capex-dependent segments contracting — raises questions about earnings durability. Analyst targets from major coverage (the consensus mean is near $279 against the current price of $213.70) suggest the Street still sees significant upside, though all notable analyst activity dates to mid-2025 and should be read as backdrop rather than current signal.
The earnings history sharpens the stakes. The last two prior-quarter prints both produced sharp declines. The February 2026 result triggered a one-day drop of 4.6% and a five-day loss of 7.6%. A comparable event in early February produced a 6.8% one-day fall. STERIS tends to move materially on its numbers, and with the stock already down about 15% year-to-date, the May 11 print will test whether that weakness reflects sufficient reset of expectations — or whether capital equipment trends remain too challenged to warrant re-rating.
See the live data behind this article on ORTEX.
Open STE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
